| Ticker: VYRX | 2159 Avenida de la Playa | |
| Exchange: NASDAQ-Small Cap Market | La Jolla, California 92037 | |
| Industry: Manufacturing | (619) 454-4446 |
| Type of Shares: | Common Shares | Filing Date: | 12/1/95 | |
| U.S. Shares: | 1,000,000 | Offer Date: | 3/21/96 | |
| Non-U.S. Shares: | 0 | Filing Price: | $6.50 | |
| Primary Shares: | 1,000,000 | Offer Price: | $6.50 | |
| Secondary Shares: | 0 | Gross Spread: | $0.63 | |
| Offering Amount: | $6,500,000 | Selling: | $0.36 | |
| Expenses: | $366,250 | Reallowance: | $0.10 | |
| Shares Out After: | 6,203,805 |
| Manager | Tier | Phone |
| First Equity Corporation of Florida | Lead Manager | (305) 379-0731 |
| Auditor: J. H. Cohn & Company | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 12/31/95 | ||||
| Revenue: | $0.01 | Assets: | $0.31 | ||
| Net Income: | -$1.85 | Liabilities: | $0.42 | ||
| EPS: | -$0.30 | Equity: | -$0.12 | ||
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company is a research and development stage company seeking to discover and develop a biopharmaceuticals for the treatment & prevention of various disorders including AIDS, asthma, cancer and aging. Vyrex is currently involved in the early stages of investigation and development of several potential research focuses mainly in the following four areas: targeting antioxidant therapeutics; annotated gene discovery utilizing the Company's proprietary CD-Tagging method; therapeutics cyclodextrins; and apoptosis-inducing cancer therapeutics. |
| Use of Proceeds |
| The company intends to apply the net proceeds over the 24 month period following the completion of this offering as follows: 1) $4 million - Research and Development and 2) $1.5 million - Working capital. |
©1996 IPO Data Systems, Inc. - All rights reserved.